Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 875045 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $209.23Day +1.76%Mkt cap $30.9BP/E (FY) 23.8×1Y +63.6%Off 52W high −4.8%Vol (1Y) 35.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 6,679 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Fair value (model)$152.59 |
| Implied upside−27.1% |
| Valuation confidenceMEDIUM |
| Price impliesAGGRESSIVE · 13.3% growth |
| Short interest4.1% of sh out |
| Days to cover3.5d |
| 13F net flow (QoQ)−1.29% |
| Top-10 13F concentration58.3% |
| Next report (est.)2026-10-28 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)23.8× |
| Sales (TTM)$9.94B |
| YTD+18.9% |
| 1Y+63.6% |
| 3Y−22.6% |
| 5Y−36.4% |
| 10Y−27.8% |
| Since incept. (ann.)+7.4% |
Total return through 2026-07-29 · series begins 2000-01-03. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)35.7% |
| Ann. volatility (3Y)30.4% |
| Sharpe (1Y)1.54 |
| Sharpe (3Y)−0.11 |
| Max drawdown (1Y)−14.3% |
| Max drawdown (3Y)−58.6% |
| Beta (3Y vs SPY)0.34 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 16.0M | $2.9B | 10.82% | +7.9% |
| PRIMECAP MANAGEMENT CO/CA/ | 14.8M | $2.7B | 10.00% | −0.0% |
| FMR LLC | 12.8M | $2.3B | 8.68% | +35.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.5M | $1.7B | 6.46% | new |
| STATE STREET CORP | 7.2M | $1.3B | 4.86% | +0.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.5M | $1.2B | 4.42% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 4.3M | $793M | 2.94% | +3.4% |
| WELLINGTON MANAGEMENT GROUP LLP | 3.0M | $543M | 2.01% | −16.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | $2.15 | +31.1% | $2.48B | +1.9% |
| 2025-12-31 | 2026-02-06 | — | — | $2.28B | −7.1% |
| 2025-09-30 | 2025-10-30 | $3.17 | +19.2% | $2.53B | +2.8% |
| 2025-06-30 | 2025-07-31 | $4.33 | +8.3% | $2.65B | +7.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-28 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
| Earnings (TTM)$1.37B |
| Net margin13.1% |
| EPS growth 3Y−25.0% |
| Sales growth 3Y−0.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
